Michael Deininger

Michael Deininger

UNVERIFIED PROFILE

Are you Michael Deininger?   Register this Author

Register author
Michael Deininger

Michael Deininger

Publications by authors named "Michael Deininger"

Are you Michael Deininger?   Register this Author

100Publications

3313Reads

5Profile Views

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1+ clones in TKI-resistant CML.

EBioMedicine 2019 Dec 21;50:111-121. Epub 2019 Nov 21.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.11.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921367PMC
December 2019

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?

Clin Cancer Res 2019 Nov 20;25(22):6561-6563. Epub 2019 Sep 20.

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-2270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858959PMC
November 2019

Design and evaluation of a subcutaneous contraceptive implant training simulator.

Int J Gynaecol Obstet 2019 Oct 17;147(1):36-42. Epub 2019 Jul 17.

Department of Mechanical Engineering, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijgo.12896DOI Listing
October 2019

BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.

Exp Hematol 2019 09 4;77:36-40.e2. Epub 2019 Sep 4.

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2019.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803074PMC
September 2019

Lysozyme nephropathy in chronic myelomonocytic leukemia.

Clin Case Rep 2019 Jun 10;7(6):1263-1264. Epub 2019 May 10.

Division of Hematology and Hematologic Malignancies University of Utah Salt Lake City Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553339PMC
June 2019

Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.

Nanomedicine 2019 02 9;16:217-225. Epub 2019 Jan 9.

Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nano.2018.12.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408272PMC
February 2019

Functional genomic landscape of acute myeloid leukaemia.

Nature 2018 10 17;562(7728):526-531. Epub 2018 Oct 17.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-018-0623-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280667PMC
October 2018

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

J Clin Oncol 2018 01 1;36(3):231-237. Epub 2017 Nov 1.

Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General Hospital, Duke-National University of Singapore Medical School, Singapore, Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, London, United Kingdom; Philipp le Coutre, Charité-Universitätsmedizin Berlin, Berlin; Andreas Hochhaus, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena; Tim H. Brümmendorf, Universitätsklinikum RWTH Aachen, Aachen, Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; Eric Leip, Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966023PMC
January 2018

Minimal Residual Disease Eradication in CML: Does It Really Matter?

Curr Hematol Malig Rep 2017 10;12(5):495-505

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Hospital, The University of Utah, Salt Lake City, UT, 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0409-7DOI Listing
October 2017

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Hematol Oncol Clin North Am 2017 08;31(4):589-612

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.04.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505321PMC
August 2017

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.

J Cancer Res Clin Oncol 2017 Jul 8;143(7):1311-1318. Epub 2017 Mar 8.

Medizinische Fakultaet Mannheim, Universität Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-017-2385-7DOI Listing
July 2017

Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?

Expert Rev Hematol 2017 07 22;10(7):659-674. Epub 2017 May 22.

c Division of Hematology and Hematologic Malignancies , Huntsman Cancer Institute, The University of Utah , Salt Lake City , UT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1330144DOI Listing
July 2017

Novice designers' use of prototypes in engineering design.

Des Stud 2017 Jul 25;51:25-65. Epub 2017 May 25.

University of Michigan, George G. Brown Laboratory, Hayward Street, Ann Arbor, MI 48109 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.destud.2017.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793937PMC
July 2017

Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Nat Rev Cancer 2017 06;17(7):425-440

INSERM U1170, Gustave Roussy, Faculté de médecine Paris-Sud, Université Paris-Saclay, F-94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2017.40DOI Listing
June 2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

N Engl J Med 2017 03;376(10):917-927

From Abteilung Hämatologie-Onkologie, Universitätsklinikum Jena, Jena, Germany (A.H.); the Department of Medicine, University of Chicago, Chicago (R.A.L.); INSERM Centre d'Investigation Clinique 1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (F.G.); Fred Hutchinson Cancer Research Center, Seattle (J.P.R.); Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide (S.B.), and the South Australian Health and Medical Research Institute and University of Adelaide (T.P.H.), Adelaide, SA, Australia; University of Bologna, Bologna, Italy (M.B.); the University of Utah Huntsman Cancer Institute, Salt Lake City (M.W.D.); the Hematology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (F.C.); Novartis, Basel, Switzerland (S.F., C.-E.O., H.D.M.); M.D. Anderson Cancer Center, Houston (H.K.); the University of Newcastle, Newcastle, United Kingdom (S.G.O.); and Knight Cancer Institute, Oregon Health and Science University and Howard Hughes Medical Institute, Portland (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965PMC
March 2017

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Cell Rep 2017 03;18(13):3204-3218

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437102PMC
March 2017

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

J Natl Compr Canc Netw 2016 12;14(12):1505-1512

From St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Memorial Sloan Kettering Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Stanford Cancer Institute; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; Fox Chase Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Roswell Park Cancer Institute; University of Colorado Cancer Center; University of Michigan Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; UCSF Helen Diller Family Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; Mayo Clinic Cancer Center; University of Wisconsin Carbone Cancer Center; National Comprehensive Cancer Network; Huntsman Cancer Institute at the University of Utah; and Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0162DOI Listing
December 2016

Molecular monitoring in CML and the prospects for treatment-free remissions.

Hematology Am Soc Hematol Educ Program 2015 ;2015:257-63

Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah; and Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2015.1.257DOI Listing
October 2016

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2016 06 29;16(6):341-349.e1. Epub 2016 Mar 29.

Department of Oncology, Hematology, and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Clinical Investigation Center, Inserm 0802, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.004DOI Listing
June 2016

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

Clin Cancer Res 2016 Mar;22(5):1037-47

Chief of Hematology, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826348PMC
March 2016

Diagnosing and managing advanced chronic myeloid leukemia.

Am Soc Clin Oncol Educ Book 2015 :e381-8

From the Huntsman Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e381DOI Listing
February 2016

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Blood 2016 Feb 24;127(6):703-12. Epub 2015 Nov 24.

Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-660977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760131PMC
February 2016

Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

J Clin Oncol 2015 Dec 14;33(35):4210-8. Epub 2015 Sep 14.

Javid J. Moslehi, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN; and Michael Deininger, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.4718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658454PMC
December 2015

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Proc Natl Acad Sci U S A 2015 Sep 8;112(39):E5381-90. Epub 2015 Sep 8.

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239; Howard Hughes Medical Institute, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1515281112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593101PMC
September 2015

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.

Exp Hematol 2015 Jul 24;43(7):537-45.e1-11. Epub 2015 Apr 24.

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2015.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487517PMC
July 2015

Aggressive systemic mastocytosis mimicking lymphoma: description of an unusual presentation and review of the literature on current management strategies.

Leuk Lymphoma 2014 Dec;55(12):2963-6

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah , Salt Lake City, UT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.910655DOI Listing
December 2014

Systemic mastocytosis in a patient with Cowden syndrome.

Am J Hematol 2014 Dec 27;89(12):1154. Epub 2014 Aug 27.

Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23815DOI Listing
December 2014

Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.

J Natl Compr Canc Netw 2014 Aug;12(8):1113-21

From the Department of Pharmacotherapy, University of Utah, and Huntsman Cancer Institute, University of Utah Health Care, Salt Lake City, Utah; Novartis Pharmaceuticals, East Hanover, New Jersey; and the Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah Health Care, and University of Utah Program in Personalized Health Care, Salt Lake City, Utah.From the Department of Pharmacotherapy, University of Utah, and Huntsman Cancer Institute, University of Utah Health Care, Salt Lake City, Utah; Novartis Pharmaceuticals, East Hanover, New Jersey; and the Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah Health Care, and University of Utah Program in Personalized Health Care, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0108DOI Listing
August 2014

The current status of ponatinib in the treatment of chronic myeloid leukemia.

Clin Adv Hematol Oncol 2014 May;12(5):329-31

University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
May 2014

Chronic Myelogenous Leukemia, Version 1.2014.

J Natl Compr Canc Netw 2013 Nov;11(11):1327-40

From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105PMC
http://dx.doi.org/10.6004/jnccn.2013.0157DOI Listing
November 2013

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Cancer Res 2013 Sep 25;73(18):5775-86. Epub 2013 Jul 25.

Authors' Affiliations: OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon; Howard Hughes Medical Institute, Chevy Chase, Maryland; Huntsman Cancer Institute; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, Utah; Novartis Institutes for BioMedical Research, Basel, Switzerland; and Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894913PMC
September 2013

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Proc Natl Acad Sci U S A 2013 Feb 16;110(6):2300-5. Epub 2013 Jan 16.

Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1206551110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568344PMC
February 2013